Abstract: Computer-generated image data is presented on first and second displays of a binocular headset presuming that a user's left and right eyes are located at first and second positions relative to the first and second displays respectively. At least one updated version of the image data is presented, which is rendered presuming that at least one of the user's left and right eyes is located at a position different from the first and second positions respectively in at least one spatial dimension. In response thereto, a user-generated feedback signal is received expressing either: a quality measure of the updated version of the computer-generated image data relative to computer-generated image data presented previously; or a confirmation command. The steps of presenting the updated version of the computer-generated image data and receiving the user-generated feedback signal are repeated until the confirmation command is received.

Abstract: There is disclosed a computer implemented eye tracking system and corresponding method and computer readable storage medium, for detecting three dimensional, 3D, gaze, by obtaining at least one head pose parameter using a head pose prediction algorithm, the head pose parameter(s) comprising one or more of a head position, pitch, yaw, or roll; and to input the at least one head pose parameter along with at least one image of a user's eye, generated from a 2D image captured using an image sensor associated with the eye tracking system, into a neural network configured to generate 3D gaze information based on the at least one head pose parameter and the at least one eye image.

Abstract: Computer-generated image data is presented on first and second displays of a binocular headset presuming that a user's left and right eyes are located at first and second positions relative to the first and second displays respectively. At least one updated version of the image data is presented, which is rendered presuming that at least one of the user's left and right eyes is located at a position different from the first and second positions respectively in at least one spatial dimension. In response thereto, a user-generated feedback signal is received expressing either: a quality measure of the updated version of the computer-generated image data relative to computer-generated image data presented previously; or a confirmation command. The steps of presenting the updated version of the computer-generated image data and receiving the user-generated feedback signal are repeated until the confirmation command is received.

Abstract: There is disclosed a computer implemented eye tracking system and corresponding method and computer readable storage medium, for detecting three dimensional, 3D, gaze, by obtaining at least one head pose parameter using a head pose prediction algorithm, the head pose parameter(s) comprising one or more of a head position, pitch, yaw, or roll; and to input the at least one head pose parameter along with at least one image of a user's eye, generated from a 2D image captured using an image sensor associated with the eye tracking system, into a neural network configured to generate 3D gaze information based on the at least one head pose parameter and the at least one eye image.

Abstract: A system and techniques for calibrating an eye tracking system are described. The system can update the calibration of personal calibration parameters continuously based on a user's gaze on a user interface, following user interface stimulus events. The system improves continuous calibration techniques by determining an association between the user's eye sequences and the stimulus events, and updates the personal calibration parameters accordingly. A record indicative of a user gaze, including eye sequences, such as eye movements or eye fixations, is maintained over a time period. A user interface stimulus event associated with the user interface and occurring within the time period is detected. An association is determined between the eye sequence and the user interface stimulus event. An interaction observation that includes the eye sequence and a location of the stimulus event is generated. Personal calibration parameters are updated based on the interaction observation.

Abstract: A system and techniques for calibrating an eye tracking system are described. The system can update the calibration of personal calibration parameters continuously based on a user's gaze on a user interface, following user interface stimulus events. The system improves continuous calibration techniques by determining an association between the user's eye sequences and the stimulus events, and updates the personal calibration parameters accordingly. A record indicative of a user gaze, including eye sequences, such as eye movements or eye fixations, is maintained over a time period. A user interface stimulus event associated with the user interface and occurring within the time period is detected. An association is determined between the eye sequence and the user interface stimulus event. An interaction observation that includes the eye sequence and a location of the stimulus event is generated. Personal calibration parameters are updated based on the interaction observation.

Abstract: A viral or non-viral vector particle having a modified viral surface protein wherein the viral surface protein is modified to include a targeting polypeptide including a binding region which binds to an extracellular matrix component. Such vector particles are useful in delivering genes encoding therapeutic agents to cells located at the site of an exposed extracellular matrix component.

Abstract: A viral or non-viral vector particle having a modified viral surface protein wherein the viral surface protein is modified to include a targeting polypeptide including a binding region which binds to an extracellular matrix component. Such vector particles are useful in delivering genes encoding therapeutic agents to cells located at the site of an exposed extracellular matrix component.

Abstract: A viral or non-viral vector particle having a modified viral surface protein wherein the viral surface protein is modified to include a targeting polypeptide including a binding region which binds to an extracellular matrix component. Such vector particles are useful in delivering genes encoding therapeutic agents to cells located at the site of an exposed extracellular matrix component.

Abstract: A viral or non-viral vector particle having a modified viral surface protein wherein the viral surface protein is modified to include a targeting polypeptide including a binding region which binds to an extracellular matrix component. Such vector particles are useful in delivering genes encoding therapeutic agents to cells located at the site of an exposed extracellular matrix component.

Abstract: A viral or non-viral vector particle having a modified viral surface protein wherein the viral surface protein is modified to include a targeting polypeptide including a binding region which binds to an extracellular matrix component. Such vector particles are useful in delivering genes encoding therapeutic agents to cells located at the site of an exposed extracellular matrix component.

Abstract: A viral or non-viral vector particle having a modified viral surface protein wherein the viral surface protein is modified to include a targeting polypeptide including a binding region which binds to an extracellular matrix component. Such vector particles are useful in delivering genes encoding therapeutic agents to cells located at the site of an exposed extracellular matrix component.

Abstract: A viral or non-viral vector particle having a modified viral surface protein wherein the viral surface protein is modified to include a targeting polypeptide including a binding region which binds to an extracellular matrix component. Such vector particles are useful in delivering genes encoding therapeutic agents to cells located at the site of an exposed extracellular matrix component.

Abstract: A retroviral vector comprising a first retroviral envelope protein and at least one modified retroviral envelope protein, wherein the first retroviral envelope protein includes a surface protein comprising (i) a receptor binding region; (ii) a hypervariable polyproline region; and (iii) a body portion, and the modified retroviral envelope protein, prior to modification, includes a surface protein which includes (i) a receptor binding region; (ii) a hypervariable polyproline region; and (iii) a body portion, characterized in that the modified retroviral envelope protein has been modified such that at least 90% of the amino acid residues of the receptor binding region of the surface protein of the modified retroviral envelope protein have been removed and replaced with a non-retroviral protein or peptide.

Abstract: A viral or non-viral vector particle having a modified viral surface protein wherein the viral surface protein is modified to include a targeting polypeptide including a binding region which binds to an extracellular matrix component. Such vector particles are useful in delivering genes encoding therapeutic agents to cells located at the site of an exposed extracellular matrix component.

Abstract: A method for expressing a recombinant protein from bone marrow-derived cells comprises the steps of treating the bone marrow-derived cells in vitro with a TGF?1 protein, which selects a population of the cells for further treatment. The selected cells can then be expanded, after which a gene encoding a therapeutic protein can be inserted into the expanded cells and thereafter express the therapeutic protein. The transduced cells can then be introduced into a mammal to produce a therapeutic result.

Abstract: Methods of treating tumors, preventing restenosis, and treating hyperplasias, corneal haze, and cataracts by administering to an animal a mutated cyclin G1 protein. The mutated cyclin G1 protein may be administered to an animal by administering to an animal an expression vehicle, such as a retroviral vector comprising a gene construct encoding a mutated cyclin G1 protein.

Abstract: A retroviral vector comprising a first retroviral envelope protein and at least one modified retroviral envelope protein, wherein said first retroviral envelope protein includes a surface protein comprising (i) a receptor binding region; (ii) a hypervariable polyproline region; and (iii) a body portion, and said modified retroviral envelope protein, prior to modification, includes a surface protein which includes (i) a receptor binding region; (ii) a hypervariable polyproline region; and (iii) a body portion, characterized in that said modified retroviral envelope protein has been modified such that at least 90% of the amino acid residues of the receptor binding region of said surface protein of said modified retroviral envelope protein have been removed and replaced with a non-retroviral protein or peptide.

Abstract: A viral or non-viral vector particle having a modified viral surface protein wherein the viral surface protein is modified to include a targeting polypeptide including a binding region which binds to an extracellular matrix component. Such vector particles are useful in delivering genes encoding therapeutic agents to cells located at the site of an exposed extracellular matrix component.

Abstract: A method for expressing a recombinant protein from bone marrow-derived cells comprises the steps of treating the bone marrow-derived cells in vitro with a TGF&bgr;1 protein, which selects a population of the cells for further treatment. The selected cells can then be expanded, after which a gene encoding a therapeutic protein can be inserted into the expanded cells and thereafter express the therapeutic protein. The transduced cells can then be introduced into a mammal to produce a therapeutic result.